mTOR-Rictor-EGFR axis in oncogenesis and diagnosis of glioblastoma multiforme

• Published in: Molecular biology reports Vol. 48; no. 5; pp. 4813 - 4835
• Main Authors: Ramaiah, M. Janaki, Kumar, K. Rohil
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.05.2021; Springer Nature B.V
• Subjects: 1-Phosphatidylinositol 3-kinase; AKT protein; Animal Anatomy; Animal Biochemistry; Biomedical and Life Sciences; Brain cancer; Cancer; Cell proliferation; Chemoresistance; Chemotherapy; Epidermal growth factor; Epidermal growth factor receptors; Extracellular signal-regulated kinase; Glioblastoma; Histology; Inositol; Kinases; Life Sciences; MAP kinase; Metabolism; MicroRNAs; miRNA; Morphology; Non-coding RNA; Protein-serine/threonine kinase; Raf protein; Rapamycin; Review; Signal transduction; TOR protein; Tumorigenesis; mTOR; Rictor; Glioblastoma multiforme (GBM); EGFR; Temozolomide (TMZ); HDAC
• ISSN: 0301-4851; 1573-4978
• DOI: 10.1007/s11033-021-06462-2

Glioblastoma multiforme (GBM) is one of the aggressive brain cancers with patients having less survival period upto 12–15 months. Mammalian target of rapamycin (mTOR) is a serine/threonine kinase, belongs to the phosphatidylinositol 3-kinases (PI3K) pathway and is involved in various cellular processes of cancer cells. Cancer metabolism is regulated by mTOR and its components. mTOR forms two complexes as mTORC1 and mTORC2. Studies have identified the key component of the mTORC2 complex, Rapamycin-insensitive companion of mammalian target of rapamycin (Rictor) plays a prominent role in the regulation of cancer cell proliferation and metabolism. Apart, growth factor receptor signaling such as epidermal growth factor signaling mediated by epidermal growth factor receptor (EGFR) regulates cancer-related processes. In EGFR signaling various other signaling cascades such as phosphatidyl-inositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR pathway) and Ras/Raf/mitogen-activated protein kinase/ERK kinase (MEK)/extracellular-signal-regulated kinase (ERK) -dependent signaling cross-talk each other. From various studies about GBM, it is very well established that Rictor and EGFR mediated signaling pathways majorly playing a pivotal role in chemoresistance and tumor aggressiveness. Recent studies have shown that non-coding RNAs such as microRNAs (miRs) and long non-coding RNAs (lncRNAs) regulate the EGFR and Rictor and sensitize the cells towards chemotherapeutic agents. Thus, understanding of microRNA mediated regulation of EGFR and Rictor will help in cancer prevention and management as well as a future therapy.